British group Acacia Pharma said on Friday it had priced its initial public offering on the Brussels stock exchange, raising 40 million euros ($49.09 million).
The company, which specializes in treatments of nausea and vomiting for post-operative and chemotherapy patients, said it would use the proceeds to prepare the launch of its first product.
“Brussels really is an extremely good market for a company like ours,” Chief Executive Julian Gilbert told Reuters, adding that companies of a similar profile had performed well after listing there.
The group says it targets a potential market of some 16 million patients annually in the United States with BAREMSIS, its first product treating post-operative nausea, expected to be launched in 2019.
While there are similar products, so-called dopamine antagonists, on the market already, the company said its product did not have safety issues associated with others.
“We have found a safe dopamine antagonist, which gives us a unique position,” Gilbert said.“There is a big opportunity for us in rescue treatment.”
Acacia Pharma is also carrying out phase 2 clinical trials for its next product aimed at chemotherapy patients.
Shares of the company, which will have a market capitalization of some 190 million euros, will start trading in Brussels on March 5.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.